Dr. Littman received the 2016 Vilcek Prize for his extraordinary achievements in immunology research, specifically, his contributions to insights on HIV pathogenesis, the specificity of the human immune response, and the interplay of the immune system with the human microbiome. The Vilcek Foundation works to raise awareness of immigrant contributions to American society through biomedical research. Dr. Littman serves as a Professor of Pathology and Microbiology at the Skirball Institute of Biomolecular Medicine of New York University School of Medicine. Orca Pharmaceuticals (www.orcapharmaceuticals.com) is based on his discoveries.
Orca Pharmaceuticals has entered into a transaction with Brickell Biotech, a clinical-stage pharmaceutical company focused on the development of dermalotology therapeutics, in which Brickell will assume the responsibility for the continued development of these RORy inhibitors.
“We are excited about this new agreement with Orca Pharmaceuticals and look forward to having the opportunity to develop a topically applied, potent and selective small-molecule therapeutic for psoriasis,” said Patricia Walker, M.D., Ph.D., President and Chief Scientific Officer of Brickell Biotech.
Dr Michael Hunter, CEO of Orca Pharmaceuticals commented, “We are delighted to partner this program with Brickell Biotech. Brickell's deep knowledge of dermatological development will be invaluable in bringing these much needed treatments to patients".
Orca Pharmaceuticals and AstraZeneca announced a partnership to develop inhibitors against a wide range of autoimmune diseases. Orca will receive upfront and milestone payments from AstraZeneca with a potential total value of $122.5 million.
Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project.
Orca Pharmaceuticals, a new biotechnology start-up focused on treating autoimmune diseases, has today announced its formation. Funding is from BioMotiv, a Cleveland, Ohio based therapeutics accelerator affiliated with The Harrington Project, and the New York University Innovation Venture Fund. The company, located in Oxford UK, is based on technology developed by inventors from New York University (NYU) in collaboration with the founders in the United Kingdom.